WebDoctor Encyclopedia

Genitourinary

Small cell neuroendocrine carcinoma of the bladder

Small cell carcinoma of the bladder is a rare, fast-growing bladder cancer that looks like small cell lung cancer. It usually causes blood in the urine and is treated with platinum chemotherapy followed by bladder removal or chemoradiotherapy.

Medically reviewed Last reviewed October 20, 2026

What is small cell neuroendocrine carcinoma of the bladder?

Small cell neuroendocrine carcinoma of the bladder is a rare and fast-growing bladder cancer. Under the microscope, its cells are small, crowded and have very little cytoplasm. They look almost identical to small cell lung cancer, the best-known cancer of this type (Ismaili, 2011).

The word neuroendocrine refers to features the cells share with hormone-producing nerve-like cells. The cancer is also called small cell carcinoma of the bladder or, in older texts, oat cell carcinoma.

Most bladder cancers are urothelial carcinomas, which start in the lining of the bladder. Small cell carcinoma makes up only a small fraction of bladder cancers, but it behaves much more aggressively. It tends to grow deeply into the bladder wall and to spread early to lymph nodes, liver, bones and lungs. Many people are diagnosed at an advanced stage (Ismaili, 2011).

The cancer is often found mixed with ordinary urothelial carcinoma in the same tumour. Genetic studies suggest that both may come from the same original cell, with the small cell part developing from a pre-existing urothelial cancer (Wang et al., 2019).

Treatment borrows from both small cell lung cancer and bladder cancer care. For disease confined to the bladder, the most effective approach is usually chemotherapy first, followed by removal of the bladder (radical cystectomy). Radiotherapy with chemotherapy is an alternative for people who cannot have surgery.

1. Key facts at a glance

Feature Details
Type of cancer High-grade neuroendocrine carcinoma of the bladder
How common Rare; a small fraction of all bladder cancers
Who is affected Mostly men in their 60s and 70s
Main symptom Visible blood in the urine
Appearance Indistinguishable from small cell lung cancer under the microscope
Mixed tumours Often found together with urothelial carcinoma
Main treatment Platinum-based chemotherapy, then cystectomy or radiotherapy
Spread Early to lymph nodes and distant organs
Outlook Poor overall; better when found early and treated with combined therapy

2. Types

Type Description Notes
Pure small cell carcinoma Only small cell cancer present Generally poorer outlook (Ismaili, 2011)
Mixed small cell carcinoma Small cell cancer together with urothelial carcinoma or another type Common; treated as small cell cancer
Large cell neuroendocrine carcinoma A related, even rarer high-grade tumour Treated in a similar way

How it differs from ordinary bladder cancer

Feature Small cell carcinoma Urothelial carcinoma
Frequency Rare The most common bladder cancer
Growth rate Very fast Usually slower
Depth at diagnosis Usually muscle-invasive or beyond Often superficial
Early spread Common Less common
First treatment for localised disease Chemotherapy before surgery Surgery, sometimes with chemotherapy
Chemotherapy regimens Small cell regimens (etoposide with a platinum) Urothelial regimens (for example gemcitabine with cisplatin)

Is it lung cancer that has spread?

Because the cells look the same as small cell lung cancer, doctors will check the lungs with a CT scan. The diagnosis of bladder small cell carcinoma is made when the bladder is the main site, often supported by an accompanying urothelial component.

3. Causes and risk factors

Risk factor Notes
Smoking The main risk factor for bladder cancer in general
Male sex More common in men (Erdem et al., 2016)
Older age Usually seventh and eighth decades
Chemical exposure at work Dyes, rubber and some industrial chemicals raise bladder cancer risk
Existing urothelial cancer The small cell component may develop from it

Where does the cancer come from?

Theory Explanation
Common clone with urothelial carcinoma Shared genetic changes suggest both arise from the same cell (Wang et al., 2019)
Multipotent stem cell An immature cell that can develop in different directions (Ismaili, 2011)
Neuroendocrine cells in the bladder lining Earlier theory, now considered less likely

4. How does it look

On cystoscopy and scans

Test Typical findings
Cystoscopy A large, solid, sometimes ulcerated tumour, often on the side walls or base
CT urogram Bladder mass, thickened wall, enlarged lymph nodes
MRI of the pelvis Depth of invasion
CT of the chest and abdomen Spread to lungs, liver or nodes; excludes a lung primary
PET-CT Detects spread not seen on CT
Bone scan or brain MRI If symptoms suggest spread

Under the microscope

Feature Description
Cells Small, round or oval, with very little cytoplasm
Nuclei Finely granular (“salt and pepper”) chromatin; nuclei mould against each other
Activity Many dividing cells and areas of dead tissue
Neuroendocrine markers Synaptophysin, chromogranin, CD56 or INSM1 often positive
Proliferation (Ki-67) Very high

Diagnosis follows the same WHO criteria used for small cell lung cancer (Erdem et al., 2016). Even if neuroendocrine stains are negative, the typical appearance is enough.

5. Symptoms

Common symptoms

  • Blood in the urine (haematuria), usually visible, the most frequent symptom (Erdem et al., 2016)
  • Passing urine more often or urgently
  • Pain or burning when passing urine

Less common symptoms

Symptom Possible cause
Pelvic or back pain Local spread or swollen nodes
Swollen legs Pressure on veins or lymph channels
Bone pain Spread to bone
Weight loss and tiredness Advanced disease
Headaches or confusion Spread to the brain
Hormone-related symptoms Rarely, the tumour makes hormones, causing low sodium or high calcium

When to seek medical advice

Blood in the urine should always be checked by a doctor, even if it happens only once and there is no pain. Most causes are not cancer, but bladder cancer needs to be excluded.

6. Diagnosis

Test Purpose
Urine tests Exclude infection; look for abnormal cells
Flexible cystoscopy Views the bladder lining
Transurethral resection of bladder tumour (TURBT) Removes tumour tissue for diagnosis and shows how deep it goes
CT of chest, abdomen and pelvis Staging and excludes a lung primary
MRI of the pelvis Local extent
PET-CT Distant spread
Brain MRI Considered because small cell cancers can spread to the brain
Kidney function and blood tests Fitness for cisplatin

Staging

The cancer is staged with the TNM system used for urothelial bladder cancer (Ismaili, 2011). Doctors also group cases in the way used for small cell lung cancer.

Group Meaning Typical treatment
Limited (localised) disease Confined to the bladder and nearby tissue, possibly with nearby nodes Chemotherapy, then cystectomy or chemoradiotherapy
Extensive (metastatic) disease Spread beyond the pelvis or to distant organs Chemotherapy, sometimes with immunotherapy

7. Treatment

There are no randomised trials in this disease. Treatment is based on retrospective studies and on experience with small cell lung cancer (Erdem et al., 2016). Care should be planned by a multidisciplinary team experienced in bladder and neuroendocrine cancers.

Disease that can be removed

Step Details
Neoadjuvant chemotherapy Usually four cycles of a platinum drug with etoposide
Radical cystectomy Removal of the bladder and nearby lymph nodes, with a new way of passing urine
Further chemotherapy Sometimes given after surgery if not given before

Four cycles of chemotherapy followed by cystectomy is regarded as the most effective sequence for resectable disease (Ismaili, 2011). Surgery alone is not enough, because hidden spread is common (Erdem et al., 2016).

In a 20-year single-centre review of 38 patients, no single treatment was clearly superior in statistical terms. However, most long-term survivors had received platinum chemotherapy followed by cystectomy, and almost half of those given chemotherapy first had their tumour downstaged (Jung et al., 2017).

When surgery is not suitable

Option Notes
Chemoradiotherapy Chemotherapy combined with radiotherapy to the bladder; preserves the bladder
Radiotherapy alone For less fit patients
Prophylactic brain radiotherapy Sometimes discussed, as in small cell lung cancer

Advanced disease

Treatment Notes
Cisplatin or carboplatin with etoposide Standard first treatment
Immunotherapy Drugs such as atezolizumab or durvalumab are used with chemotherapy in small cell lung cancer and are sometimes extended to bladder cases
Second-line chemotherapy For example topotecan or other regimens
Palliative radiotherapy Controls bleeding or pain
Clinical trials Including new targeted drugs such as those directed at DLL3

Side effects

Treatment Possible side effects
Platinum and etoposide chemotherapy Low blood counts, infection, tiredness, hair loss, nausea, hearing and kidney effects with cisplatin
Radical cystectomy Wound and urinary problems, changes in sexual function, need for a stoma or new bladder
Radiotherapy to the bladder Frequent urination, bowel irritation, tiredness
Immunotherapy Inflammation of organs such as bowel, lungs, liver or glands

Living with a urinary diversion

Type What it means
Ileal conduit Urine drains through a stoma into a bag on the abdomen
Neobladder A new bladder made from bowel, emptied by passing urine normally
Continent pouch An internal pouch emptied with a catheter

Recovery after cystectomy

Period What to expect
Hospital stay Usually 5-10 days
First 6 weeks Gradual return to walking and light activity; no heavy lifting
2-3 months Most people return to many normal activities
Longer term Adjusting to the stoma or neobladder, with specialist nurse support

8. Outlook (prognosis)

Factor Effect
Stage at diagnosis The most important factor (Erdem et al., 2016)
Pure small cell histology Poorer than mixed tumours
Chemotherapy followed by cystectomy Linked with the best long-term results
Spread to distant organs Poor outlook

In the Fox Chase review, median survival was just under 12 months, and around 1 in 7 patients were alive at five years (Jung et al., 2017). People with early-stage disease who complete combined treatment can achieve long survival.

Survival in the Fox Chase series

Time Overall survival
1 year About 47%
3 years About 26%
5 years About 14%

9. Follow-up

Time Typical follow-up
First 2 years Review and CT scans every 3 months
Years 3-5 Every 6 months
If the bladder is kept Regular cystoscopy
New symptoms Brain MRI or other scans as needed
Long term Kidney function, vitamin B12 and stoma care checks

Better molecular understanding of this cancer may help to improve follow-up and treatment in future (Wang et al., 2019).

10. Living with small cell bladder cancer

  • Stop smoking; your team can help with medicines and support
  • Report fever promptly during chemotherapy
  • Drink plenty of fluids unless told otherwise
  • Learn stoma care with a specialist nurse if you have a urinary diversion
  • Ask about sexual function after surgery; treatments and aids are available
  • Keep active with regular walks, which help recovery and energy levels
  • Carry a list of your treatments in case you need urgent care elsewhere
  • Seek support from bladder cancer charities and stoma support groups

11. Frequently asked questions

Question Answer
Is it lung cancer? No, it starts in the bladder, although it looks the same under the microscope
Why chemotherapy before surgery? It treats hidden spread early and may shrink the tumour
Can I keep my bladder? Chemoradiotherapy may be an option in some cases
Is it caused by smoking? Smoking is the main risk factor for bladder cancer generally
Will I need a stoma? Possibly, after cystectomy; some people can have a neobladder
How long does chemotherapy take? Four cycles usually take about three months
Can it be cured? Yes, in some people with early disease treated with combined therapy
Is it inherited? No
Will I lose my hair? Often, with etoposide-based chemotherapy, but it grows back

12. Questions to ask your care team

  • Is my cancer pure or mixed small cell carcinoma?
  • Has it spread beyond the bladder?
  • Do you recommend chemotherapy before surgery?
  • Is bladder-preserving treatment possible for me?
  • What type of urinary diversion would suit me?
  • Do I need a brain scan?
  • Are there any clinical trials I could join?
  • What support is there for adjusting to life after treatment?

Resources

  1. Erdem, G.U. et al. (2016) ‘Small cell carcinoma of the urinary bladder: changing trends in the current literature’, Current Medical Research and Opinion, 32(6), pp. 1013-1021.
  2. Ismaili, N. (2011) ‘A rare bladder cancer – small cell carcinoma: review and update’, Orphanet Journal of Rare Diseases, 6, 75.
  3. Jung, K. et al. (2017) ‘Small-cell carcinoma of the bladder: 20-year single-institution retrospective review’, Clinical Genitourinary Cancer, 15(3), pp. e337-e343.
  4. Wang, Y. et al. (2019) ‘Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up’, Medical Oncology, 36(12), 98.
  5. National Cancer Institute (2026) Bladder Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.